M. Heaney

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
Mark L Heaney, Mark Heaney, M. Heaney, M L Heaney, Mark L. Heaney
Publication record
138 papers · 7,270 citations · H-index 36

PAPERS

Can the treatment of myeloproliferative neoplasms be both good and bad for you?
20220 citationsauthor #1
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database.
20214 citationsauthor #5
Review for "Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia‐positive acute lymphoblastic leukaemia"
20210 citationsauthor #1
Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments
20216 citationsauthor #21
Glasdegib in newly diagnosed acute myeloid leukemia
20219 citationsauthor #2
Abstract CT023: PATHFINDER: Interim analysis of avapritinib (ava) in patients (pts) with advanced systemic mastocytosis (AdvSM)
20212 citationsauthor #19
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.
2020110 citationsauthor #11
Erdheim-Chester disease: Consensus recommendations for the evaluation, diagnosis, and treatment in the molecular era.
2020315 citationsauthor #2
Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis
20205 citationsauthor #9
Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.
202064 citationsauthor #4
PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis (SM) With Symptoms Inadequately Controlled by Standard Therapy
202012 citationsauthor #9
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase.
202063 citationsauthor #23
Minimal Residual Disease Eradication with Venetoclax in Acute Myeloid Leukemia
20200 citationsauthor #5
Review for "Favourable outcome of chronic myeloid leukemia co‐expressing e13a2 and e14a2 transcripts, treated with nilotinib"
20200 citationsauthor #1
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
202058 citationsauthor #34
Review for "Genetic alteration patterns and clinical outcomes of elderly and secondary acute myeloid leukemia"
20190 citationsauthor #1
Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.
201927 citationsauthor #7
Review for "The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors"
20190 citationsauthor #1
Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database
20194 citationsauthor #4
Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38-44].
20191 citationsauthor #7
Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy
20193 citationsauthor #7
Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience
20190 citationsauthor #2
Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia
201852 citationsauthor #27
Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial)
20187 citationsauthor #8
Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients
20189 citationsauthor #11
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.
201855 citationsauthor #14
Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms
201818 citationsauthor #17
Quality improvement and safety curriculum for hematology/oncology fellows at Columbia University.
20180 citationsauthor #2
Phase I/II trial of glasdegib in patients with primary or secondary myelofibrosis.
20171 citationsauthor #7
A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis
201721 citationsauthor #15
Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis
20178 citationsauthor #7
Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies
20160 citationsauthor #3
Safety and Efficacy of Combined Ruxolitinib and Decitabine in Patients with Blast-Phase MPN and Post-MPN AML: Results of a Phase I Study (Myeloproliferative Disorders Research Consortium 109 trial)
201614 citationsauthor #16
A Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies
20160 citationsauthor #3
Key Data Elements in Myeloid Leukemia
20166 citationsauthor #8
Treatment Outcomes in CML Patients Treated With Tyrosine Kinase Inhibitors at a Tertiary Teaching Hospital in South Africa.
20156 citationsauthor #4
Abstract A28: Use of a high-throughput screen of primary leukemia cells to personalize therapy for relapsed/refractory AML: Proof of concept and clinical implementation of precision medicine.
20150 citationsauthor #2
Abstract B10: A novel high-throughput screen of primary leukemia cells to personalize therapy for relapsed/refractory acute myeloid leukemia (AML): Proof of concept and clinical implementation of precision medicine
20150 citationsauthor #3
AUY922, a Heat Shock Protein 90 (Hsp90) Inhibitor, Demonstrates Activity in Patients with Myeloproliferative Neoplasms (MPNs)
201510 citationsauthor #8
A phase I trial of a pharmacodynamically-conceived decitabine/thioguanine combination in patients with advanced myeloid malignancies.
20150 citationsauthor #3
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
201562 citationsauthor #9
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.
2014564 citationsauthor #9
Acute Myeloid Leukemia With t(9;11) (p22;q23) and Synchronous Langerhans Cell Histiocytosis
20146 citationsauthor #3
Evaluation of response to first-line treatment for chronic myeloid leukemia: has imatinib been outperformed?
20140 citationsauthor #2
Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers
201445 citationsauthor #5
Sequencing treatment in chronic myeloid leukemia: the first choice may be the hardest.
20143 citationsauthor #1
Genomic Analysis of Serial Samples from CLL Patients Identifies Clonal Events Associated with Disease Progression
20140 citationsauthor #22
Multidimensional Single-Cell Analysis of BCR Signaling Reveals Proximal Activation Defect As a Hallmark of Chronic Lymphocytic Leukemia B Cells
201413 citationsauthor #9
The Warburg Effect Confers Adverse Outcome in Chronic Lymphocytic Leukemia
20140 citationsauthor #14
A Phase I Trial of a Pharmacodynamically-Conceived Decitabine and Thioguanine Combination in Patients with Advanced Myeloid Malignancies
20142 citationsauthor #2
Extensive High-Depth Sequencing Of Longitudinal CLL Samples Identifies Frequent Mutations In MAP Kinase Signaling and Novel Mutations Activating Notch and Beta-Catenin
20132 citationsauthor #19
A Self-Assembling Short Oligonucleotide Duplex Suitable for Pretargeting
201313 citationsauthor #6
Evaluation Of Afuresertib, An Oral Pan-AKT Inhibitor, In Patients With Langerhans Cell Histiocytosis
201310 citationsauthor #17
Acute Myeloid Leukemia Following a Myeloproliferative Neoplasm: Clinical Characteristics, Genetic Features and Effects of Therapy
201316 citationsauthor #1
Clinical Implementation of a Novel High-Throughput Screen of Primary Leukemia Cells to Personalize Therapy for Relapsed/Refractory Acute Myeloid Leukemia (AML)
20130 citationsauthor #2
proteasome inhibitors in lymphoid malignancies The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of
20130 citationsauthor #2
Saving orphans: BRAF targeting of histiocytosis.
201310 citationsauthor #1
Myeloid growth factors.
2013161 citationsauthor #7
pharmacodynamics myelodysplastic syndrome: safety, pharmacokinetics, and antagonist, in patients with acute myelogenous leukemia or high-risk Phase 1 clinical results with tandutinib (MLN518), a novel FLT3
20130 citationsauthor #13
Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications.
20139 citationsauthor #2
Churg–Strauss Syndrome with Eosinophilic Myocarditis
20125 citationsauthor #3
High Dose Cytarabine and Mitoxantrone in Combination with Dasatinib As Active Induction Therapy in Adult Patients with Philadelphia Chromosome Positive (ph+) Acute Lymphoblastic Leukemia (ALL)
20120 citationsauthor #5
Safety and efficacy of dose escalated liposomal amphotericin B in adult leukemia patients with refractory invasive fungal infections: A single institution report.
20120 citationsauthor #6
Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia.
20122 citationsauthor #12
A new paradigm in CLL: Minimizing toxicity by using the minimum effective dose (MED) of lenalidomide for older patients with CLL.
20122 citationsauthor #2
Micafungin Versus Posaconazole Anti-Fungal Prophylaxis in Adult Patients with Acute Leukemia Undergoing Induction Chemotherapy
20121 citationsauthor #9
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.
201252 citationsauthor #2
Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History
20110 citationsauthor #11
NCCN Myeloid Growth Factors Clinical Practice Guidelines in Oncology
20111 citationsauthor #6
Chronic myelomonocytic leukemia (CMML) associated with symptomatic pericardial effusion.
20114 citationsauthor #3
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.
20111,266 citationsauthor #24
Myeloid Growth FactorsPractice Guidelines in Oncology
20112 citationsauthor #6
increased glucose uptake in human melanoma cells Granulocyte-macrophage colony-stimulating factor signals for
20111 citationsauthor #2
Myeloid growth factors.
20114 citationsauthor #6
Decitabine for the treatment of acute myeloid leukemia (AML): Memorial Sloan-Kettering Cancer Center experience.
20113 citationsauthor #5
Influence of National Comprehensive Cancer Network (NCCN) Guidelines on Clinical Practice in Patients with Chronic Myelogenous Leukemia (CML) Treated At a Single Academic Medical Center
20115 citationsauthor #4
Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia
2010237 citationsauthor #7
A Phase I Study of the Potent Hsp90 Inhibitor STA-9090 Administered Twice Weekly In Subjects with Hematologic Malignancies
20107 citationsauthor #3
High Mitochondrial Membrane Potential Identifies Patients with Myeloproliferative Neoplasms with a More Aggressive Natural History
20102 citationsauthor #9
A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia
2010182 citationsauthor #6
Characteristic Proinflammatory Serum Cytokine Profiles In Patients with B-Cell Chronic Lymphocytic Leukemia
20100 citationsauthor #7
Reply to Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy‐induced neutropenia
20100 citationsauthor #1
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
201086 citationsauthor #15
Inhibition of Human Peptide Deformylase Disrupts Mitochondrial Function
201047 citationsauthor #7
Clinical Cancer esearch cer Therapy : Clinical uential Cytarabine and α-Particle Immunotherapy Bismuth-213 – Lintuzumab ( HuM 195 ) for R te Myeloid Leukemia
20100 citationsauthor #8
Myeloid growth factors.
200919 citationsauthor #13
Discovery and Validation of a Novel Class of Small Molecule Inhibitors of the CDC7 Kinase: Modulation of Tumor Cell Growth in Vitro and In Vivo.
20092 citationsauthor #6
Clinical Implementation of a Novel High-Throughput Screen of Primary Leukemia Cells to Customize Therapy for Relapsed/Refractory Acute Myeloid Leukemia (AML).
20090 citationsauthor #3
PCN8 COMPARISON OF INFECTION-RELATED HOSPITALIZATION RISK AND ASSOCIATED COSTS AMONG PATIENTS RECEIVING SARGRAMOSTIM, FILGRASTIM, AND PEGFILGRASTIM FOR CHEMOTHERAPY-INDUCED NEUTROPENIA
20095 citationsauthor #8
Multivalent DNA Aptamer-Based Therapeutic Agents for Lymphoma and Leukemia.
20090 citationsauthor #9
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.
200975 citationsauthor #7
Abstract B255: Discovery and validation of a novel class of small molecule inhibitors of the CDC7 kinase: Modulation of tumor cell growth in vitro and in vivo
20092 citationsauthor #6
Soluble GM-CSF Receptor α Is Cytotoxic to Myeloid Cells in a Manner That Is Independent of GM-CSF Binding Inhibition.
20090 citationsauthor #2
New advances in the pathogenesis and therapy of essential thrombocythemia.
200817 citationsauthor #2
Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213 (213Bi)-Labeled-HuM195 (Lintuzumab) for Acute Myeloid Leukemia (AML)
20085 citationsauthor #6
Multiple erythematous eroded patches and papules on the scalp.
20083 citationsauthor #4
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.
2008146 citationsauthor #11
Small Molecule Inhibition of Cdc7, a Key Cell Cycle Regulator and Novel Therapeutic Target, Successfully Inhibits Leukemia Cell Growth in Vitro and in Vivo
20082 citationsauthor #7
The Novel Human Ph+ Acute Lymphoblastic Leukemia Cell Line PhALL3.1 Is Amenable to Retroviral Gene Transfer and Mimics Human Disease Progression in SCID-Beige Mice
20080 citationsauthor #3
Comparison of Infection-Related Hospitalization Risk and Associated Costs among Patients Receiving Sargramostim (Leukine®), Filgrastim (Neupogen®), and Pegfilgrastim (Neulasta®) for Chemotherapy-Induced Neutropenia
20080 citationsauthor #8

TIMELINE

1986 48 citations

1987 36 citations

1994 58 citations

1995 137 citations

1998 231 citations

1999 10 citations

2000 73 citations

2002 30 citations

2003 228 citations

2004 146 citations

2005 1,195 citations

2006 921 citations

2007 43 citations

2008 300 citations

2009 103 citations

2010 561 citations

2011 1,286 citations

2012 62 citations

2013 221 citations

2014 633 citations

2015 78 citations

2016 20 citations

2017 30 citations

2018 141 citations

2019 35 citations

2020 627 citations

2021 21 citations

2022 0 citations

M. Heaney

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT